The goal of this cohort study is to observe the effectiveness of Yiqi Fumai Lyophilized Injection (YQFM) in patients with acute heart failure (AHF). It mainly aims to assess the effectiveness of YQFM on the 90-day mortality or readmission rate in patients with AHF and compare the results with AUGUST-AHF RCT study. There will be no intervention, but information will be collected during the hospital stay and during the follow-up period of 180 days . Researchers will compare exposed group(patients who received YQFM) and non-exposed group(patients who didn't received YQFM) to see if there is difference on the 90-day mortality or readmission rate.
It mainly aims to assess the effectiveness of YQFM on the 90-day mortality or readmission rate in patients with AHF and compare the results with AUGUST-AHF RCT study. There will be no intervention, but patients will be asked to answer questions(such as scales or reporting of symptoms ) and provide biochemical or imaging tests, as well as undergo regular follow-up. Researchers will compare exposed group(patients who received YQFM) and non-exposed group(patients who didn't received YQFM) to see if there is difference on the 90-day mortality or readmission rate. We will also collect information on medication adherence during the follow-up period and remotely test patients during the follow-up period
Study Type
OBSERVATIONAL
Enrollment
1,200
No intervention was involved, but patients will be divided into exposed or non-exposed groups based on whether they received YQFM
Dongzhimen Hospital
Beijing, Beijing Municipality, China
RECRUITINGThe First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang
Guiyang, Guizhou, China
NOT_YET_RECRUITINGThe Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine
Guiyang, Guizhou, China
NOT_YET_RECRUITING90-day all-cause mortality or readmission for HF
90-day all-cause mortality or readmission for HF
Time frame: 90-day
180-day all-cause mortality or HF readmission
180-day all-cause mortality or HF readmission
Time frame: 180-day
cardiac-specific death
cardiac-specific death
Time frame: 180 day
MACE
major cardiovascular adverse event
Time frame: 180 day
length of hospital stay
the length of patients staying in hospital
Time frame: during the hospitalization of patients, an average of 10 days
dyspnoea via visual analogue scale (VAS)
Dyspnea VAS scores range from a maximum of 10 to a minimum of 0. Higher scores mean a worse outcome. 10 means extreme dyspnea, and 0 means no dyspnea.
Time frame: during the hospitalization of patients, an average of 10 days
dyspnoea via Likert 7-point scale
The Likert 7-point scores range from a maximum of 7 to a minimum of 1. Higher scores mean a better outcome.
Time frame: during the hospitalization of patients, an average of 10 days
NYHA cardiac function classification
New York Heart Association cardiac function classification
Time frame: 180 day
Minnesota Living with Heart Failure Quality of Life (MLHFQ) scale
Likert 7-point scores range from a maximum of 105 to a minimum of 0. Higher scores mean a worse outcome.
Time frame: 180 day
Morisky Medication Adherence Scale (MMAS)-8 scale
MMAS-8 scores range from a maximum of 8 to a minimum of 0. Higher scores mean a better outcome
Time frame: 180 day
heart rate
heart rate
Time frame: 180 day
number of participants eligible for the randomized controlled trial of AUGUST-AHF
Patients will complete a questionnaire with the help of researchers. This questionnaire includes the inclusion criteria for another study, the randomized controlled trial of AUGUST-AHF. After the patient has completed the questionnaire, the investigator will determine whether the patient meets the criteria based on the results
Time frame: at admission
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.